Vaxcyte, Inc. (1PCVX)

Profile

https://vaxcyte.com

Vaxcyte, Inc. is a clinical-stage biotechnology company specializing in the development of next-generation vaccines to combat bacterial infectious diseases. Its pipeline is centered on innovative conjugate and novel protein vaccines, with key candidates such as VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease, and VAX-31, a complementary 31-valent conjugate vaccine in development for adults and children. The company also explores vaccines targeting diseases like Group A Streptococcus and periodontitis, leveraging advanced chemistry and a proprietary cell-free protein synthesis platform to enhance vaccine efficacy and scale production. Vaxcyte’s focus on high-fidelity, broad-spectrum vaccines aims to address limitations of traditional cell-based vaccine manufacturing, targeting pathogens responsible for significant global morbidity and mortality. Headquartered in San Carlos, California, and founded in 2013, Vaxcyte plays a pivotal role in the healthcare sector by striving to set new standards in immunization against life-threatening bacterial infections, with a vision of protecting vulnerable populations such as infants and older adults worldwide.